Kangtai Biotechnology: Trivalent Influenza Split Vaccine Initiates Phase I Clinical Trial.

Kangtai Biological announced that the trivalent influenza virus split vaccine developed by the company and Lanzhou Biotech Co., Ltd. has completed the preparation work for Phase I clinical trials, initiated the Phase I clinical trial, and successfully enrolled the first subject today.